天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Home Cart 0 Sign in  

[ CAS No. 1228947-14-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1228947-14-5
Chemical Structure| 1228947-14-5
Structure of 1228947-14-5 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 1228947-14-5 ]

Related Doc. of [ 1228947-14-5 ]

Alternatived Products of [ 1228947-14-5 ]
Product Citations

Product Details of [ 1228947-14-5 ]

CAS No. :1228947-14-5 MDL No. :MFCD20259655
Formula : C10H19NO2 Boiling Point : No data available
Linear Structure Formula :- InChI Key :AIFIVCWONKRRJQ-UHFFFAOYSA-N
M.W : 185.26 Pubchem ID :58205557
Synonyms :

Calculated chemistry of [ 1228947-14-5 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 0
Fraction Csp3 : 1.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 55.01
TPSA : 32.7 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.29 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.25
Log Po/w (XLOGP3) : 0.2
Log Po/w (WLOGP) : 0.24
Log Po/w (MLOGP) : 0.64
Log Po/w (SILICOS-IT) : 1.17
Consensus Log Po/w : 0.9

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.05
Solubility : 16.6 mg/ml ; 0.0894 mol/l
Class : Very soluble
Log S (Ali) : -0.45
Solubility : 66.4 mg/ml ; 0.359 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -0.7
Solubility : 37.1 mg/ml ; 0.2 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.55

Safety of [ 1228947-14-5 ]

Signal Word:Warning Class:
Precautionary Statements:P280-P305+P351+P338 UN#:
Hazard Statements:H302 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 1228947-14-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1228947-14-5 ]

[ 1228947-14-5 ] Synthesis Path-Downstream   1~14

  • 1
  • [ 5414-19-7 ]
  • [ 27489-62-9 ]
  • [ 1228947-14-5 ]
YieldReaction ConditionsOperation in experiment
With triethylamine; In acetonitrile; at 60℃; (0392) Trans-4-Aminocyclohexanol (0.5 g), 1-bromo-2-(2-bromoethoxyl)ethane (1.07 g) and triethylamine (2.42 ml) were dissolved in anhydrous acetonitrile (20 ml). The reaction mixture was heated at 60 C. overnight. The organic solvent was removed under vacuum. The residue was purified with flash column chromatography on silica gel eluting with 7%-10% methanol in dichloromethane to give the title compound.
  • 2
  • [ 64-18-6 ]
  • [ 62226-17-9 ]
  • [ 1228947-14-5 ]
  • 4-[4-(thieno[2,3-b]pyridin-4-yloxy)cyclohexyl]morpholine formate [ No CAS ]
YieldReaction ConditionsOperation in experiment
32% 131. 4-(4-[thieno[2,3-b]pyridin-4-yloxy]cyclohexyl)morpholine.Page 221 of 4072009184-0008 Molecular Weight: 169.63 Molecular Weight: 379.191Into a 50-mL round-bottom flask, was placed a solution of 4-(morpholin-4-yl)cyclohexan-l-ol (164 mg, 0.89 mmol, 1.50 equiv) in N,N-dimethylformamide (15 mL), sodium hydride (47 mg, 1.96 mmol, 2.00 equiv). The resulting mixture was stirred at 80 C for 30 minutes. Then 4- chlorothieno[2,3-b]pyridine (100 mg, 0.59 mmol, 1.00 equiv) was added to the mixture. The resulting solution was stirred for 4 h at 120C in an oil bath. The reaction was then quenched by the addition of 5 mL of water. The resulting solution was extracted with 3x30 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x 15 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (10: 1). The crude product (120 mg) was purified by Prep-HPLC with the following conditions: Column, SunFire Prep C18, 19* 150mm 5um; mobile phase, CH3CN and water with 0.05% HCOOH (10.0% water with 0.05% HCOOH up to 50.0% in 10 min, up to 100.0% in 2 min, down to 10.0% in 2 min); Detector, uv 254/220nm. This resulted in 72.2 mg (32%) of 4-(4-[thieno[2,3- b]pyridin-4-yloxy]cyclohexyl)morpholine as a white semi-solid. MS:(ES,/n/z): 319.10 [M+H]+ NMR (400 MHz, O20, ppm): 51.53-1.71 (m, 4H), 2.19-2.33 (dd, Jl= 29.7 Hz , J2= 9.3Hz, 4H), 3.24-3.30(m, 3H),3. 1(m, 2H), 4.07(s, 2H), 4.60(m, 1H), 6.98(d, J= 4.5 Hz , 1H), 7.37(d, J= 4.5Hz , 1H), 7.52(d, J= 4.5Hz , 1H), 8.33(d, J= 4.5Hz , 1H).
  • 3
  • [ 1228947-14-5 ]
  • [ 1388894-15-2 ]
  • 4
  • [ 1228947-14-5 ]
  • [ 1388894-16-3 ]
  • 5
  • [ 1228947-14-5 ]
  • [ 1388894-17-4 ]
  • 6
  • [ 1228947-14-5 ]
  • [ 1388894-05-0 ]
  • [ 1388894-14-1 ]
YieldReaction ConditionsOperation in experiment
63% Example 29: Synthesis of 2-((R)-4-(((lr,4R)-4-morpholinocyclohexyl)oxy)-6,7- dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-5-yl)acetamide.Page 280 of 4072009184-0008 33b[00638] Synthesis of compound 31b. 4-(Morpholin-4-yl)cyclohexan-l-ol (commercially available; 218 mg, 1.2 mmol, 1.50 equiv) was treated with NaH NMR (60% dispersion in mineral oil, 128 mg, 3.2 mmol, 4 equiv) in freshly distilled tetrahydrofuran (15 mL) for 30 min at 0 C in a water/ice bath under nitrogen. Then a solution of intermediate Hb (289 mg, 0.8 mmol, 1.00 equiv) in 5 mL of THF was added via syringe and the resulting solution was allowed to stir for an additional 3 h at 60 C in an oil bath. The reaction was then quenched with saturated aqueous NH4CI and extracted with 3 x 50 mL of ethyl acetate. The combined organic layers were washed with brine, dried (Na2S04) and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 :5-1 :2) and purified to afford compound 31b (260 mg, 63%) as a colorless oil.[00639] Synthesis of compound 32b. To a solution of 31b (260 mg, 0.5 mmol, 1.0 equiv) in 10 mL of DCM was added 0.5 mL of concentrated hydrochloric acid in an ice/water bath. The resulting solution was stirred for 2 h and concentrated in vacuo. The residue was neutralized with saturated aqueous Na2C( j and extracted with 3 x 50 mL of ethyl acetate. The organic layers were combined, washed with brine, dried (Na2S04) and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with DCM/MeOH NMR ( 15: 1 ) to afford the desired alcohol 32b ( 185 mg, 91 %) as a colorless oil.[00640] Synthesis of compound 33b. Alcohol 32b (185 mg, 0.46 mmol, 1.00 equiv) was oxidized with dipyridinium dichromate (752 mg, 2.00 mmol, 4.36 equiv) in 50 mL of DMF forPage 281 of 4072009184-0008 24 h at room temperature. The resulting solution was diluted with water and extracted with 3 x 50 mL of mixed solutions of CHCU/iso-PrOH. The organic layers were combined, dried (Na2S04) and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (5: 1 to 1 : 1 ) and purified to afford 105 mg (55%) of acid 33b as a yellow oil.[00641] Synthesis of Compound. A 50 mL round-bottom flask containing a solution of acid 33b (105 mg, 0.25 mmol, 1.00 equiv), NH4C1 (80 mg, 1.50 mmol, 6.00 equiv), EDCI (57 mg, 0.3 mmol, 1.2 equiv), 4-dimethylaminopyridine (37 mg, 0.3 mmol, 1.2 equiv) and HOBt (40 mg, 0.3 mmol, 1.2 equiv) in 5 mL of anhydrous DMF was stirred for 24 h at room temperature. The resulting solution was diluted with water and extracted with 4 x 50 mL of mixed solution of CHCI3: iso-PrOH. The combined organic layers were concentrated under vacuum. The crude product was purified by preparative HPLC (SHIMADZU) under the following conditions: column: SunFire Prep C I 8, 19* 150mm 5um; mobile phase: water (0.05% Nu??3) and CH3CN (6.0% CH3CN up to 50.0% in 25 min); UV detection at 254/220 nm. The product containing fractions were collected and concentrated to give the product (22.5 mg) as a white solid. MR (300 MHz, CD3OD) delta 8.43 (s, 1H), 5.27-5.20 (m, 1H), 3.80-3.70 (m, 5H), 3.29-3.27 (m, 1 H), 3.12-2.90 (m, 2H), 2.73-2.67 (m, 5H), 2.49-2.42 (m, 1H), 2.32-2.19 (m, 4H), 2.10-2.06 (d, 2H), 1.67- 1.46 (m, 4H). MS: m/z 417 (M+H)+.
  • 7
  • [ 1228947-14-5 ]
  • [ 1447956-33-3 ]
  • C26H36N8O2S [ No CAS ]
YieldReaction ConditionsOperation in experiment
200mg Into a 50-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 4- (morpholin-4-yl)cyclohexan-l-ol (111 mg, 0.60 mmol, 1.20 equiv) in 5 mL of distilled THF at 0 C. This was followed by the addition of NaHMDS (0.75 mL, 2 M in THF) dropwise via a syringe and stirring for 30 min. To a solution of 202.9 (135 mg, 0.50 mmol, 1.00 equiv) in 2 mL of THF was added and the resulting solution was stirred for 2 h at 0 C. The reaction was then quenched by the addition of 5 mL of water and the pH value of the solution was adjusted to 5 with 1 M hydrochloric acid and extracted with 5 x 10 mL of chloroform/i-PrOH (3: 1). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum to give the resultant 1-234 (200 mg, crude) as a white solid. MS (ES): m/z 418 (M+H)+. 'H-NMR (400 MHz ,CDC13): delta 8.48 (1H, s), 5.25-5.12 (1H, m), 3.87 (4H, brs), 3.30 (1H, dd), 3.08-2.74 (9H, m), 2.45-2.25 (3H, m), 2.19-1.88 (3H, m), 1.80-1.50 (4H, m).
  • 8
  • [ 1228947-14-5 ]
  • 5,6-dihydro-6,6-dimethyl-4-chloro-8H-pyrano[4',3':4,5]thieno[2,3-d]pyrimidine [ No CAS ]
  • [ 1447952-51-3 ]
YieldReaction ConditionsOperation in experiment
66% 207.4 1-193 [001073] Sodium hydride (118.1 mg, 2.95 mmol, 5.01 equiv, 60%) was treated with trans- 4-(morpholin-4-yl)cyclohexan-l-ol (218.7 mg, 1.18 mmol, 2.00 equiv) in 10 mL of distilled THF for 30 min under nitrogen. 207.4 (150.2 mg, 0.59 mmol, 1.00 equiv) was added and the resulting solution was stirred for 3 h at 55 C. After cooled down to rt, the reaction was then quenched by the addition of NH4CI (aq.) and extracted with 3 x 60 mL of DCM. The combined organic layers were dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (20: 1) to provide the desired 158.1 mg (66%) of 1-193 as an off-white solid. MS (ES): m/z 404 (M+H)+. 'H-NMR (300 MHz, CD3OD): delta 8.49 (1H, s), 5.35-5.15 (1H, m), 3.72 (4H, t), 2.93 (2H, s), 2.63 (4H, t), 2.45-2.25 (3H, m), 2.15-2.02 (2H, m), 1.69-1.40 (4H, m), 1.34 (6H, s).
  • 9
  • [ 1228947-14-5 ]
  • [ 1447957-40-5 ]
  • [ 1447957-43-8 ]
  • 10
  • [ 1228947-14-5 ]
  • [ 1447957-40-5 ]
  • [ 1447957-41-6 ]
  • [ 1447957-42-7 ]
YieldReaction ConditionsOperation in experiment
30%; 76mg ?ras-4-(Morpholin-4-yl)cyclohexan-l-ol (76 mg, 0.41 mmol, 1.20 equiv) was treated with NaHMDS (0.25 mL, 1.50 equiv) in 6 mL of distilled THF for 20 min at 0 C under nitrogen. Then a solution of 254.7 (100 mg, 0.32 mmol, 1.00 equiv) in dry THF (3 mL) was added via syringe. After stirring for lh at this temperature, the reaction was then quenched with water and extracted with 3 x 20 mL of ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:10) to give 45 mg (30%) of 254.8 as a white solid. 76 mg of by-product 254.9 were also obtained as a white solid.
  • 11
  • [ 1228947-14-5 ]
  • [ 1521711-12-5 ]
  • [ 1533422-03-5 ]
YieldReaction ConditionsOperation in experiment
62.7 mg To a solution of trans-4-(morpholin-4-yl)cyclohexan-l-ol (213 mg, 1.15 mmol, 2.00 equiv) in distilled N,N-dimethylformamide (10 mL) was added sodium hydride (69 mg, 2.88 mmol, 3.00 equiv, 60% dispersion in mineral oil) at room temperature and the resulting solution was stirred for 0.5 h at 80 C in an oil bath under nitrogen. Then a solution of 12-chloro-7- thiatricyclo[6.4.0.0A[2,6]]dodeca-l(12),2(6),8,10-tetraene (120 mg, 0.57 mmol, 1.00 equiv) in 3 mL of DMF was added via syringe and the resulting mixture was stirred at 80 C for 3 hours. After cooling, the reaction was quenched with water and extracted with 5 x 50 mL of dichloromethane. The combined organic layers were dried over sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by preparative HPLC under the following conditions (Waters): Column: Xbridge Prep C18, 5 muiotaeta, 19*50m; water (with 0.05%> NH4HC03) and CH3CN (10% CH3CN up to 40% CH3CN in 10 min); flow rate: 20 mL/min; UV detection at 254 nm. The product-containing fractions were collected and partially evaporated to remove water and CH3CN under reduced pressure. The residue was lyophilized overnight to give the desired 4-(4-[7-thiatricyclo[6.4.0.0A[2,6]]dodeca-l(12),2(6),8,10-tetraen-12- yloxy]cyclohexyl)morpholine (62.7 mg) as a white solid. MS (ES): m/z 359 (M+H)+. 1H NMR (300 MHz, CDC13): delta 1.51-1.72 (4H, m), 1.82-2.06 (2H, m), 2.22-2.30 (3H, m), 2.42-2.50 (2H, m), 2.68 (4H, m), 2.78-3.06 (4H, m), 3.51-3.96 (4H, m) , 4.30-4.48 (1H, m), 6.63 (1H, d, J = 5.4Hz), 8.25 (1H, d, J= 5.4Hz).
  • 12
  • [ 1228947-14-5 ]
  • [ 40142-92-5 ]
  • [ 1537184-66-9 ]
YieldReaction ConditionsOperation in experiment
29 mg Sodium hydride (70 mg, 1.75 mmol, 3.00 equiv, 60% dispersion in mineral oil) was treated with trans-4-(morpholin-4-yl)cyclohexan-l-ol (214 mg, 1.16 mmol, 2.00 equiv) in 20 mL of distilled THF at room temperature for 30 minutes. Then 4-chlorobenzo[4,5]thieno[2,3- d]pyrimidine (128 mg, 0.58 mmol, 1.00 equiv) was added to the mixture and the resulting solution was stirred for 5 h at room temperature. The reaction was then quenched by the addition of 5 mL of H20, extracted with 3 x 30 mL of dichloromethane. The organic layers were combined, washed with brine, dried over sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (Waters): Column, Xbridge Prep CI 8, 5um, 19* 50mm; mobile phase, water with 0.05%> NH4HCO3 and CH3CN (10% CH3CN up to 35% in 10 min, up to 95% in 1.5 min, down to 10% in 1.5 min); Flow rate: 20 mL/min; UV detection at 254/220 nm. This resulted in 29 mg of 4-((lr,4r)-4- (benzo[4,5]thieno[2,3-d]pyrimidin-4-yloxy)cyclohexyl)morpholine as a white solid. LC-MS: (ES, m/z) 370 (M+H+). 1H-NMR (300 MHz, CD3OD) delta 1.45-1.60 (2H, m), 1.66-1.80 (2H, m), 2.10 (2H, m), 2.41 (2H, m), 2.68 (4H, m), 3.78 (4H, m), 5.40 (1H, m), 7.52-7.56 (2H, m), 7.96 (1H, m), 8.40 (1H, m), 8.65 (1H, s).
  • 13
  • [ 1228947-14-5 ]
  • [ 1537184-75-0 ]
  • [ 1537184-76-1 ]
YieldReaction ConditionsOperation in experiment
68% Into a 50-mL 3-necked round-bottom flask containing a solution of trans-4- (morpholin-4-yl)cyclohexan-l-ol (85 mg, 0.46 mmol, 1.93 equiv) in anhydrous tetrahydrofuran (4 mL) was added sodium hydride (60%> dispersion in mineral oil, 80 mg, 2.00 mmol, 8.42 equiv) at 0C under nitrogen. After stirred for 1 h at room temperature, a solution of 6-(2-((tert- butyldimethylsilyl)oxy)ethyl)-4-chlorobenzo[4,5]thieno[2,3-d]pyrimidine (90 mg, 0.24 mmol, 1.00 equiv) in THF (3 mL) was added and the resulting solution was stirred overnight at ambient temperature. The reaction was then quenched with water, extracted with 3 x 50 mL of ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1/1) to provide 85 mg (68%) of the corresponding 4-((lr,4r)-4-((6- (2-((tert-butyldimethylsilyl)oxy)ethyl)benzo [4,5 Jthieno [2,3 -d]pyrimidin-4- yl)oxy)cyclohexyl)morpholine as a white solid. LCMS (ES, m/z): 528 (M+H+).
  • 14
  • [ 64-18-6 ]
  • [ 1228947-14-5 ]
  • [ 24391-41-1 ]
  • 4-(trans-(4-morpholinocyclohexyl)oxy)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile*0.7(formic acid) [ No CAS ]
YieldReaction ConditionsOperation in experiment
34% To a solution of trans-4-(morpholin-4-yl)cyclohexan-l-ol (520 mg, 2.81 mmol, 5.01 equiv) in tetrahydrofuran (10 mL) was added sodium hydride (360 mg, 9.00 mmol, 16.07 equiv, 60%)). The resulting solution was stirred for 0.5 h at 0C. Then 4-chloro-7H-pyrrolo[2,3- d]pyrimidine-5-carbonitrile (100 mg, 0.56 mmol, 1.00 equiv) was added. The resulting solution was stirred for 16 h at 70C. The reaction was then quenched by the addition of 2 mL of water. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions: Column, Xbridge Prep CI 8 5um, 19* 150mm; mobile phase, water with 0.1% HCOOH and CH3CN (5.0% CH3CN up to 40.0% in 12 min, up to 92.0% in 2 min, down to 5.0% in 2 min); Detector, 220/254nm. This resulted in 70.2 mg (34%) of 4-(tra/75-(4-morpholinocyclohexyl)oxy)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile as a white solid. LC-MS: (ES,m z): 328[M-0.7HCOOH+H] + 1H NMR (300 MHz, DMSO, ppm): 51.54-1.88 (m, 4H), 2.13-2.14 (m, 2H), 2.16-2.23 (m, 2H), 2.27-2.29 (m, 1H), 2.45-2.55 (m, 4H), 3.46-3.55 (m, 4H), 5.14-5.21 (m, 1H) , 8.09 (s, 0.7H), 8.27 (s, 1H), 8.50 (s, 1H), 12.97 (brs, 0.9H).
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 1228947-14-5 ]

Alcohols

Chemical Structure| 1588441-09-1

[ 1588441-09-1 ]

trans-4-Morpholinocyclohexanol hydrochloride

Similarity: 0.97

Chemical Structure| 5835-79-0

[ 5835-79-0 ]

4-Morpholinobutan-1-ol

Similarity: 0.79

Chemical Structure| 61168-09-0

[ 61168-09-0 ]

4-(Dimethylamino)cyclohexanol

Similarity: 0.76

Chemical Structure| 3554-62-9

[ 3554-62-9 ]

1-Isopropylpiperidin-3-ol

Similarity: 0.74

Chemical Structure| 681851-40-1

[ 681851-40-1 ]

((2R,3R)-2-Methylmorpholin-3-yl)methanol hydrochloride

Similarity: 0.72

Related Parent Nucleus of
[ 1228947-14-5 ]

Aliphatic Heterocycles

Chemical Structure| 1588441-09-1

[ 1588441-09-1 ]

trans-4-Morpholinocyclohexanol hydrochloride

Similarity: 0.97

Chemical Structure| 412356-24-2

[ 412356-24-2 ]

trans-4-Morpholinocyclohexanamine dihydrochloride

Similarity: 0.88

Chemical Structure| 53617-35-9

[ 53617-35-9 ]

4-Morpholinopiperidine

Similarity: 0.83

Chemical Structure| 5835-79-0

[ 5835-79-0 ]

4-Morpholinobutan-1-ol

Similarity: 0.79

Chemical Structure| 139025-93-7

[ 139025-93-7 ]

4-Morpholinocyclohexanone

Similarity: 0.77

Morpholines

Chemical Structure| 1588441-09-1

[ 1588441-09-1 ]

trans-4-Morpholinocyclohexanol hydrochloride

Similarity: 0.97

Chemical Structure| 412356-24-2

[ 412356-24-2 ]

trans-4-Morpholinocyclohexanamine dihydrochloride

Similarity: 0.88

Chemical Structure| 53617-35-9

[ 53617-35-9 ]

4-Morpholinopiperidine

Similarity: 0.83

Chemical Structure| 5835-79-0

[ 5835-79-0 ]

4-Morpholinobutan-1-ol

Similarity: 0.79

Chemical Structure| 139025-93-7

[ 139025-93-7 ]

4-Morpholinocyclohexanone

Similarity: 0.77

; ;